Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.

Gupta, Mehul; Stukalin, Igor; Meyers, Daniel; Goutam, Sid; Heng, Daniel Y C; Cheng, Tina; Monzon, Jose; Navani, Vishal

Gupta, Mehul; Stukalin, Igor; Meyers, Daniel; Goutam, Sid; Heng, Daniel Y C; Cheng, Tina; Monzon, Jose; Navani, Vishal.

Afiliação

Gupta M; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Stukalin I; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Meyers D; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Goutam S; Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
Heng DYC; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Cheng T; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Monzon J; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.
Navani V; Division of Medical Oncology, Department of Oncology, Tom Baker Cancer Centre, Calgary, Alberta, Canada.

JAMA Netw Open ; 6(6): e2319607, 2023 Jun 01.

Article em En | MEDLINE | ID: mdl-37351883

Assuntos

Melanoma; Nivolumabe; Masculino; Humanos; Idoso; Pessoa de Meia-Idade; Ipilimumab/uso terapêutico; Estudos de Coortes; Melanoma/patologia; Alberta

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Nivolumabe / Melanoma Tipo de estudo: Clinical_trials / Etiology_studies / Incidence_studies / Observational_studies / Risk_factors_studies Limite: Aged / Humans / Male / Middle aged País/Região como assunto: America do norte Idioma: En Revista: JAMA Netw Open Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google